Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani S.
Pitisuttithum P, et al.
Lancet Infect Dis. 2018 Nov;18(11):1260-1268. doi: 10.1016/S1473-3099(18)30375-X. Epub 2018 Sep 25.
Lancet Infect Dis. 2018.
PMID: 30266329
Clinical Trial.
Seroconversion rates for IgG antibodies against pertussis toxin and FHA were also greater in the aP((PTgen/FHA)) group (82%, 95% CI 71-93 and 64%, 51-77, respectively) and TdaP((PTgen/FHA)) group (75%, 63-87 and 56%, 42-70, respectively) than in the Tdap group (4%, 0-9, p<0.00 …
Seroconversion rates for IgG antibodies against pertussis toxin and FHA were also greater in the aP((PTgen/FHA)) group (82%, 95% CI 71-93 an …